MarketScreener

Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder

The FDA first approved it in 2014 to treat Non-24-Hour Sleep-Wake Disorder in adults, and in 2020 to treat nighttime sleep disturbances in people with Smith-Magenis Syndrome. The DSWPD program would ...

Blueberries can modify the gut microbiome in older adults with mild depression

A new pilot study found that older, sedentary adults who consumed blueberries daily showed a greater, more consistent ...
MarketScreener

Phathom Pharmaceuticals, Inc. Initiates Registrational Phase 3 Study Of VOQUEZNA For As-Needed Treatment Of Non-Erosive GERD

Phathom Pharmaceuticals, Inc. announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an as-needed (PRN or on-demand) investigational dosing ...

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces ...

VYD2311 met all primary and secondary endpoints comparing VYD2311 to an mRNA-based COVID-19 vaccine, demonstrating VYD2311 safety and tolerability that is clinically and statistically superior to the ...
Contagion Live

VYD2311 Shows Superior Tolerability to mRNA COVID-19 vaccine in Phase 3 Study

The investigational monoclonal antibody, VYD2311, (Invivyd) met all primary and key secondary endpoints in the phase 3 LIBERTY study. It showed safety and tolerability superior to an mRNA-based ...